Biopharmaceutical company Ajinomoto Bio-Pharma Services (Aji Bio-Pharma) said on Wednesday that it has entered into a manufacturing agreement with Humanigen Inc for the fill finish supply of lenzilumab, currently being studied in Phase III clinical trial in adult, hospitalised patients with COVID-19.
Pursuant to the agreement, Aji Bio-Pharma will provide drug product aseptic fill finish services for Humanigen at its San Diego facility.
Lenzilumab, Humanigen's proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, is being administered as part of a US FDA-approved multi-centre, randomised, placebo-controlled, double-blinded Phase III study for COVID-19 patients. Lenzilumab neutralises GM-CSF, a key cytokine in the initiation of a cytokine storm.
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis
Hemogenyx Pharmaceuticals partners with Made Scientific to advance CAR-T therapy
Lilly's Jaypirca delivers breakthrough results in front-line CLL trial